- Conditions
- Breast Neoplasms, Neoplasm Metastasis
- Interventions
- Temsirolimus (CCI-779) for 34 months, Letrozole for 34 months
- Drug
- Lead sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 1,236 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 112
- States / cities
- Hoover, Alabama • Huntsville, Alabama • Tucson, Arizona + 98 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 60
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Multiple Myeloma
- Interventions
- carfilzomib
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 164 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 26
- States / cities
- Scottsdale, Arizona • Beverly Hills, California • Laguna Hills, California + 23 more
- Conditions
- Arthritis, Juvenile Rheumatoid, Crohn Disease
- Interventions
- somatropin [rDNA origin] for injection
- Drug
- Lead sponsor
- Nationwide Children's Hospital
- Other
- Eligibility
- 5 Years to 17 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Short Bowel Syndrome
- Interventions
- Growth Hormone
- Drug
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 19 Years to 78 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2008
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Alzheimer Disease
- Interventions
- Bapineuzumab 0.5 mg/kg
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 51 Years to 90 Years
- Enrollment
- 494 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 66
- States / cities
- Birmingham, Alabama • Goodyear, Arizona • Phoenix, Arizona + 38 more
- Conditions
- Obesity, Obesity; Drug, Lifestyle, Healthy
- Interventions
- Online Lifestyle Behavioral Therapy, Phentermine Hydrochloride 8 MG
- Behavioral · Drug
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 870 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Saint Louis Park, Minnesota • Winston-Salem, North Carolina + 1 more
- Conditions
- Obesity, Overweight
- Interventions
- WW Clinic, Bupropion-Naltrexone, Bupropion-Naltrexone-Metformin
- Behavioral · Drug
- Lead sponsor
- WW International Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 226 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Mantle Cell Lymphoma
- Interventions
- VELCADE TM (bortezomib) for Injection
- Drug
- Lead sponsor
- Millennium Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 152 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2003
- U.S. locations
- 35
- States / cities
- Birmingham, Alabama • Berkeley, California • Duarte, California + 26 more
- Conditions
- SARS-CoV-2 Infection
- Interventions
- 25 µg SpFN_1B-06-PL + ALFQ (QS21 Adjuvant), Sodium chloride, USP, for injection (0.9% NaCl), 50 µg SpFN_1B-06-PL + ALFQ (QS21 Adjuvant)
- Biological · Drug
- Lead sponsor
- U.S. Army Medical Research and Development Command
- Federal
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Silver Spring, Maryland
- Conditions
- Gulf War Illness
- Interventions
- Draw blood (phlebotomy, 83 ml)
- Other
- Lead sponsor
- Georgetown University
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Overweight and Obesity
- Interventions
- AVOID, RESIST
- Behavioral
- Lead sponsor
- Cedars-Sinai Medical Center
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Beverly Hills, California
- Conditions
- Overweight and Obesity
- Interventions
- WW (formerly Weight Watchers), Waitlist
- Behavioral
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years to 60 Years · Female only
- Enrollment
- 61 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- PreDiabetes
- Interventions
- Registered Dietitian/Nutritionist, Diabetes Prevention Program, Weight Watchers, Reimagined, DPP or RDN Counseling + Medication, Bariatric Surgery Evaluation
- Behavioral · Other
- Lead sponsor
- Geisinger Clinic
- Other
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Danville, Pennsylvania
- Conditions
- Acute Lymphoblastic Leukemia (ALL)
- Interventions
- Carfilzomib, Dexamethasone, Mitoxantrone, PEG-asparaginase, Vincristine, Intrathecal (IT) Methotrexate, Intrathecal Triple Therapy (Intrathecal Cytarabine, Hydrocortisone, and Methotrexate), 6-Mercaptopurine, Cyclophosphamide, Cytarabine, Daunorubicin
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 1 Month to 21 Years
- Enrollment
- 141 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2024
- U.S. locations
- 22
- States / cities
- Oakland, California • Orange, California • Aurora, Colorado + 19 more
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- VELCADE™ (bortezomib) for Injection (formerly PS-341)
- Drug
- Lead sponsor
- Millennium Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 155 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2002
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 15 more
- Conditions
- Cigarette Smoking, Alcohol Consumption
- Interventions
- Varenicline, Placebo pill (for varenicline), Alcohol, placebo beverage (for alcohol)
- Drug
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 21 Years to 55 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Wrinkles
- Interventions
- onabotulinumtoxinA, JUVÉDERM
- Drug
- Lead sponsor
- AboutSkin Dermatology and DermSurgery, PC
- Industry
- Eligibility
- 25 Years to 65 Years
- Enrollment
- 156 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Englewood, Colorado
- Conditions
- Penicillin Allergy
- Interventions
- Amoxicillin 250 MG, Placebo, Amoxicillin 62.5mg, Amoxicillin 187.5mg
- Drug
- Lead sponsor
- James Tarbox, MD
- Other
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 380 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Lubbock, Texas
- Conditions
- Osteoporosis
- Interventions
- BZA 20 mg/CE 0.45 mg, BZA 20 mg/CE 0.625 mg, Raloxifene 60 mg, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 40 Years to 75 Years · Female only
- Enrollment
- 507 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 22
- States / cities
- Fort Myers, Florida • Gainesville, Florida • New Port Richey, Florida + 19 more
- Conditions
- Alcohol Abuse, Alcohol Use Disorder
- Interventions
- Stand-alone web-based cognitive behavioral therapy (CBT4CBT) for alcohol use disorder
- Behavioral
- Lead sponsor
- Virginia Commonwealth University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 248 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Richmond, Virginia
- Conditions
- Hepatitis C
- Interventions
- GS-9669 tablets, Placebo to Match GS-9669 tablet
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 82 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 10
- States / cities
- Los Angeles, California • DeLand, Florida • Orlando, Florida + 6 more
- Conditions
- Colorectal Carcinoma
- Interventions
- VELCADE TM (bortezomib) for Injection, or PS-341
- Drug
- Lead sponsor
- Millennium Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 175 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2002
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Pine Bluff, Arkansas + 18 more
- Conditions
- Lung Neoplasms
- Interventions
- Indocyanine Green
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Multiple Myeloma
- Interventions
- Carfilzomib, Dexamethasone
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 478 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 12
- States / cities
- Scottsdale, Arizona • Bethesda, Maryland • Rockville, Maryland + 4 more